Trial Profile
A Phase 3, Multicenter, Single-arm, Open-label, Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of Intravenous Peramivir in Elderly Subjects With Acute Uncomplicated Influenza Infection and in Subjects With Acute Uncomplicated Influenza Infection at Higher Risk for Influenza Complications
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Peramivir (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors BioCryst Pharmaceuticals
- 03 Oct 2018 Status changed from recruiting to completed.
- 28 Dec 2015 New trial record